NO donor type substituted coumarin-furazan conjugate and anti-tumor activity

By designing coumarin derivatives and furazole conjugates containing different substituents at 3,4,8-positions, the problem of insufficient selective inhibition of existing anti-tumor drugs on multidrug-resistant cells is solved, and the non-response is achieved The efficient inhibition of small-cell lung cancer cells and multi-pathway induced death provide new anti-tumor treatment options.

CN118930530APending Publication Date: 2024-11-12FUDAN UNIVERSITY

Patent Information

Application Number
CN202310523515.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-10
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

Existing anti-tumor drugs have poor selective inhibition of multidrug-resistant tumor cells and are difficult to induce tumor cell death through multiple pathways, especially in non-small cell lung cancer cells.

Method used

A series of coumarin derivatives and furazole conjugates containing different substituents at positions 3,4,8-positions were designed to significantly improve the inhibition of P-gp overexpression resistant cells by improving water solubility and structural optimization. and induced apoptosis by inducing nitric oxide release, reactive oxygen generation and ferrodynamic pathways, enhances the anti-proliferative activity against non-small cell lung cancer cells.

Benefits of technology

It significantly improves the selective inhibitory effect of multidrug-resistant cells, enhances the anti-proliferative activity of non-small cell lung cancer cells, and induces cell death through various pharmacological mechanisms, providing a new anti-tumor treatment strategy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004221982610000041
    Figure BDA0004221982610000041
  • Figure BDA0004221982610000051
    Figure BDA0004221982610000051
  • Figure BDA0004221982610000061
    Figure BDA0004221982610000061
Patent Text Reader

Abstract

The invention belongs to the field of chemical pharmacy, and particularly relates to a conjugate formed by combining 3, 4, 8-site coumarin derivatives containing different substituent groups with furazan nitrogen oxide through two-carbon linkage, and experiments prove that the conjugate has better water solubility and has excellent inhibitory activity on the growth of sensitive human tumor cells and drug-resistant tumor strain cells. Preliminary pharmacological experiments show that the compound has the characteristic of relying on P-gp overexpression by releasing high-concentration nitric oxide, and has a new action mechanism of inhibiting MDR tumor growth; or the compound has the effect of inhibiting non-small cell lung cancer cell proliferation through multiple ways such as ferroptosis and apoptosis induction. The compound provided by the invention lays a foundation for subsequent in-depth research and search of new drugs which have a multi-path cancer inhibition pharmacological mechanism and overcome multi-drug resistance of breast cancer, non-small cell lung cancer and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of chemical pharmacy, and specifically relates to coumarin derivative-furoxan conjugates containing different substituents at the 3, 4, and 8 positions and their water solubility, anti-tumor activity, nitric oxide release and cell ferroptosis pharmacological mechanisms. Background Art

[0002] Nitric oxide (NO) is an important signaling molecule that can participate in the regulation of various physiological functions and can also affect the growth, proliferation and metastasis of tumor cells. Studies have shown that low concentrations of NO (less than 100nM) can promote the production of cGMP through the nitrosation of sGC, induce the formation of new blood vessels around tumor cells, and promote the growth and metastasis of tumor cells. High concentrations of NO (greater than 500nM) can produce a variety of active nitrogen oxides with nitrosation and nitrosation capabilities in tumor cells, inducing tumor cell death through DNA damage, blocking the cell cycle, and degrading anti-apoptotic proteins.

[0003] In recent years, more and more furazan derivatives have been studied in the field of anti-tumor, and furazan NO donors have become one of the hot topics of research. A series of conjugated compounds of furazan nitrogen oxides and anti-tumor drugs and their activities have been reported in the literature. For example, the Xu team obtained a conjugate by hybridizing β-elemene with furazan nitrogen oxides, which has a significant anti-proliferative effect on malignant glioma cells and can significantly inhibit the growth of mouse brain gliomas, with an inhibition rate of more than 90% (Eur J Med Chem, 2017, 135: 414-423.). In addition, the Liu team obtained the Penstatin-furazan compound by hybridizing the microtubule disruptor (Penstatin) with benzenesulfonyl furazan nitrogen oxides, which showed significant anti-proliferative activity against ovarian cancer sensitive cells (A2780) and paclitaxel-resistant ovarian cancer cells (A2780 / T), and its IC 50 The value is 0.008-0.021 μM (EurJ Med Chem, 2022, 230: 114112.). In addition, Chen's research group introduced a variety of NO donor compounds into the skeleton of dihydrochlorin (e6) to obtain Chlorin e6-furoxan hybrid, which can increase the levels of intracellular reactive oxygen species ROS and NO and has good synergistic anti-tumor activity (Chem Soc Rev, 2016, 45 (23): 6488-6519.).

[0004] Recently, the inventors of the present application further optimized the lead compound CY-16S-4A93 and obtained 28 new conjugates of coumarin derivatives with different substituents at the 3, 4, and 8 positions and furazan. The water solubility of some compounds was increased by 8-10 times compared with CY-16S-4A93. Pharmacological experiments showed that the antitumor activity of most compounds against the P-gp overexpressing adriamycin-resistant breast cancer cell line MCF-7 / ADR was significantly higher than that of its sensitive strain MCF-7. More than half of the target compounds showed similar selectivity to CY-16S-4A93, that is, they showed higher selective inhibitory activity against the breast cancer resistant strain MCF-7 / ADR. Among them, the more active compounds 13a, 13c and 6o had an antiproliferative activity against MCF-7 / ADR cells that was 1065, 615 and 431 times higher than that of MCF-7 cells, which was 405 times better than that of CY-16S-4A93.

[0005] In addition, most of the target compounds showed significant inhibitory activity against the proliferation of four sensitive lung cancer cell lines A549, H1299, H2030 and H1975 and two resistant lung cancer cell lines A549 / T and A549 / CDDP. 50 The value is less than 50nM. This type of new target compounds (6a, 6e, 6j, 6n, 6o, 6q, 6s, 13b-d, 18c and 24) can release a certain concentration of NO in A549 cells. Among them, the nitric oxide release of 12 target compounds (6a, 6e, 6j, 6n, 6o, 6q, 6s, 13b-d, 18c and 24) is higher than that of the lead compound CY-16S-4A93 (6.37μM), and the release of NO is closely related to the anti-tumor proliferation activity. Preliminary pharmacological experiments showed that the inhibitory activity of compound 6o on A549 and A549 / CDDP cells was concentration-dependent with the ferroptosis inhibitor (Fer-1). At the same time, 6o can cause increased levels of intracellular reactive oxygen species (ROS) and accumulation of lipid peroxides (MDA), and there is a pharmacological mechanism related to cell death through the ferroptosis pathway. In addition, 6o can also induce apoptosis of A549 and A549 / CDDP cells, suggesting that this type of coumarin-furoxan conjugate has the ability to inhibit the proliferation of non-small cell lung cancer cells through multiple pathways such as ferroptosis and induction of apoptosis. Summary of the invention

[0006] The purpose of the present invention is to provide a novel anti-tumor compound with clear activity, improved water solubility, high selective inhibitory effect on MDR tumor resistant strains with overexpression of P-gp, and the ability to inhibit the proliferation of non-small cell lung cancer cells through multiple pathways such as ferroptosis and apoptosis induction. Specifically, it relates to the compound 4-(2-((3-(3,5-dichlorobenzyl)-4-methyl-2-oxo-2H-chromene-7-oxy)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide (CY-20S-3A72,6o) and its derivatives and the application of the activity of inhibiting tumor growth.

[0007] The present invention is based on the original active compound CY-16S-4A93, and designs and synthesizes Figure 1 As shown, compounds of coumarin derivatives containing different substituents at the 3, 4, and 8-positions coupled with furazan have significant inhibitory activity on the proliferation of MCF-7 / ADR, A549, H1299, H2030, H1975, A549 / T and A549 / CDDP tumor cells.

[0008] In the present invention, the preferred coumarin furazan conjugate has a structure of formula I, and the conjugate of the substituted coumarin derivative and furazan is a product of formula I, wherein the 3-position of the coumarin parent nucleus is connected to benzyl and substituted phenethyl containing different substituents, such as ortho, meta, and para; the 4-position is connected to alkyl, unsubstituted aryl, and substituted aryl; the 8-position is connected to substituted aryl alkanoate methyl; and the 7-position is coupled to furazan nitrogen oxide through two carbon side chains to synthesize the product. (such as Figure 1 shown),

[0009] Where: R 1 Methyl, ethyl, propyl, phenyl, trifluoromethylphenyl

[0010] R 2 is o-, m-, p-methoxybenzyl; o-, m-, p-aminobenzyl; o-, m-, p-chlorobenzyl; o-, m-trifluoromethylbenzyl; p-bromobenzyl; m-cyanobenzyl; 3,5-dimethoxybenzyl; 3,4,5-trimethoxybenzyl; 3,5-dimethyltrifluoromethylbenzyl; 3,4-dichlorobenzyl; 2,6-dichlorobenzyl; 3,5-dichlorobenzyl; 3-chloro-4-fluorobenzyl; 3-fluoro-4-chlorobenzyl; 3-fluoro-5-chlorobenzyl; 4-aminophenethyl R 3 3,4,5-trimethoxyphenylacetyloxymethylene

[0011] The present invention provides a method for preparing the coumarin parent nucleus furazan conjugate, which comprises:

[0012] 60% sodium hydride was added to dry THF, and ethyl acetoacetate and 2a-s were added dropwise under ice bath, and the ethyl acetoacetate derivative 3a-s was obtained by nucleophilic substitution reaction; further, it was cyclized with resorcinol under 70% sulfuric acid to obtain 3-substituted coumarin parent core product 4a-s; then, it was refluxed with bromoethanol, potassium carbonate and sodium iodide in DMF to obtain 7-hydroxyethoxy-coumarin derivative 5a-s; finally, it was reacted with benzenesulfonyl furazan nitrogen oxide in dichloromethane containing DBU at room temperature to synthesize the target derivative 6a-s. The chemical reaction is as follows:

[0013] General formula 1,

[0014]

[0015] 60% sodium hydride was added to dry THF, and ethyl acetoacetate and 2t-w were added dropwise under ice bath, and the ethyl acetoacetate derivatives 7a-d were obtained by nucleophilic substitution reaction; further, the derivatives were cyclized with resorcinol under 70% sulfuric acid to obtain 3-substituted coumarin core products 8a-d; then, the derivatives were refluxed with bromoethanol, potassium carbonate and sodium iodide in DMF to obtain 7-hydroxyethoxy-coumarin derivatives 9a-d; then, the derivatives were reacted with stannous chloride dihydrate in DCM to obtain reduction products 10a-d; the reduction products 10a-d were heated with triethylamine and di-tert-butyl carbonic anhydride in DCM to obtain 3-position Boc-protected coumarin core products 11a-d; then, the derivatives were reacted with benzenesulfonylfurazan nitrogen oxide in dichloromethane containing DBU at room temperature to synthesize 12a-d; finally, the derivatives were reacted with 20% trifluoroacetic acid in DCM at room temperature to synthesize 3-position amino-containing target derivatives 13a-d. The chemical reaction is as follows:

[0016] Formula 2:

[0017]

[0018] 60% sodium hydride was added to dry THF, and ethyl acetoacetate derivatives (14a-d) and 3-chloro-4-fluorobenzyl bromide were added dropwise under ice bath, and nucleophilic substitution reaction was performed to obtain 15a-d; further, cyclization reaction with resorcinol was performed under 70% sulfuric acid to obtain 3-substituted coumarin core products 16a-d; then, reflux reaction with bromoethanol, potassium carbonate and sodium iodide in DMF was performed to obtain 7-hydroxyethoxy-coumarin derivatives 17a-d; finally, reaction with benzenesulfonyl furazan nitrogen oxide in dichloromethane containing DBU was performed at room temperature to synthesize target derivatives 18a-d. The chemical reaction is as follows:

[0019] Formula three:

[0020]

[0021] 7-Hydroxy-4-methylcoumarin and urotropine were added to glacial acetic acid, and the temperature was raised to react; when the first step reaction was basically complete, the temperature was lowered to 70°C, and 5N hydrochloric acid was added to continue the reaction to generate 8-aldehyde-4-methylcoumarin derivative 20; further refluxed with bromoethanol, potassium carbonate and sodium iodide in DMF to obtain 7-hydroxyethoxy-coumarin derivative 21; then reacted with benzenesulfonyl furazan nitrogen oxide in dichloromethane containing DBU at room temperature to synthesize coumarin furazan derivative 22; then reacted with sodium borohydride in MeOH under ice bath at room temperature to obtain 8-hydroxycoumarin furazan derivative 23; finally reacted with 3,4,5-trimethoxyphenylacetic acid, EDCI and DMAP in dichloromethane at room temperature to synthesize target derivative 24. The reaction is as follows:

[0022] Formula 4:

[0023]

[0024] The furazan derivatives (6a-s, 13a-d, 18a-d and 24) of the present invention, wherein the coumarin core with different substituents at the 3, 4 and 8 positions is coupled to the furazan nitrogen oxide through a two-carbon linker, were subjected to solubility testing and anti-tumor activity screening at the cell level. The solubility test results of the target compound in PBS (pH=7.4) showed that the water solubility of such compounds (13a-d) was increased by 8-10 times compared with the original active compound CY-16S-4A93.

[0025] In the in vitro pharmacological experiment, the antitumor activity of 28 target compounds on MCF-7 (human breast cancer cells) and MCF-7 / ADR (adriamycin-resistant human breast cancer cells) was determined with the lead compound CY-16S-4A93 as the control. Comparing the inhibition rate of the antiproliferative activity of the target compounds on the sensitive strain MCF-7 and the resistant strain MCF-7 / ADR, most of the target compounds retained the selectivity similar to that of the lead compound CY-16S-4A93, that is, they showed higher inhibitory activity on the breast cancer resistant strain MCF-7 / ADR, which is also called "subsidiary sensitivity". Among them, the cell proliferation inhibition effect of compounds 13a, 13c and 6o on breast cancer resistant cells MCF-7 / ADR was 1065, 615 and 431 times higher than that on sensitive cells MCF-7.

[0026] Next, the target compounds were used as positive controls to determine the proliferation inhibition rate of the target compounds on sensitive non-small cell lung cancer cell lines (A549, H1299, H2030 and H1975) and drug-resistant non-small cell lung cancer cell lines (A549 / T and A549 / CDDP). The experimental results showed that most of the target compounds had good anti-proliferation activity against the six non-small cell lung cancer cell lines, and the target compounds had better proliferation inhibition activity on sensitive non-small cell lung cancer cell lines (H1299, H2030, H1975 and A549) than on drug-resistant lines (A549 / T and A549 / CDDP).

[0027] In addition, the 24 target compounds can release a certain concentration of NO in A549 cells, and the anti-tumor activity is negatively correlated with the NO scavenger concentration, indicating that the anti-tumor activity of this type of compound is related to the released effective NO concentration.

[0028] Preliminary pharmacological experiments showed that the inhibitory activity of compound 6o on A549 and A549 / CDDP cells was concentration-dependent with the ferroptosis inhibitor (Fer-1); at the same time, 6o could cause increased levels of intracellular reactive oxygen species (ROS) and accumulation of lipid peroxides (MDA). In addition, 6o could also induce apoptosis of A549 and A549 / CDDP cells.

[0029] In the present invention, the solubility of the compound was tested and the biological activity was studied by the following methods.

[0030] 1. First, make a standard curve to determine the relationship between the area under the curve and solubility. Then use HPLC to detect the area under the curve of each compound and calculate the solubility.

[0031] 2. MTS method was used to determine the cytotoxicity of sensitive and resistant solid tumor cells. A blank control group, target compounds (6a-h, 6j-k, 6n-q, 6s, 13a-d, 18a-d and 24), compound CY-16S-4A93, and positive drug (cisplatin and paclitaxel) control groups were set up. After adding drugs, the cells were cultured at 37°C for 48 hours, and the MTS test was performed to calculate the inhibition rate and IC 50 Tested tumor cell lines: human breast cancer cells (MCF-7), adriamycin-resistant human breast cancer cells (MCF-7 / ADR), non-small cell lung cancer sensitive cell lines (A549, H1299, H2030 and H1975) and non-small cell lung cancer resistant cell lines (A549 / T and A549 / CDDP).

[0032] 3. Using the principle of classic Griess reagent, the “Total NO Detection Kit (Beyotime)” was used to detect the nitric oxide release level of the target compound in tumor cells A549.

[0033] 4. Use the Reactive Oxygen Species Assay Kit (Beyotime) and the Lipid Peroxidation MDAAssay Kit (Beyotime) to detect the changes in ROS and MDA levels in A549 and A549 / CDDP cells.

[0034] 5. Annexin V-FITC Apoptosis Detection Kit (Beyotime) and BD FASCS Calibur flow cytometer were used to detect the apoptosis induced by compound 6o in A549 and A549 / CDDP cells.

[0035] The 28 coumarin-furoxan conjugates described in the present invention have novel structures and improved solubility. They have the effect of highly selectively inhibiting the proliferation activity of P-gp overexpressing and resistant tumor cells, and are new anti-tumor compounds that can inhibit the proliferation of non-small cell lung cancer cells through multiple pathways such as ferroptosis and induction of apoptosis. This lays a foundation for subsequent in-depth research to find new drugs with multi-pathway anti-cancer pharmacological mechanisms to overcome the multidrug resistance of breast cancer, non-small cell lung cancer, etc. BRIEF DESCRIPTION OF THE DRAWINGS

[0036] Figure 1 Structural formula of a series of 3,4,8-substituted coumarin-furoxan conjugates.

[0037] Figure 2 Effects of NO scavengers on antitumor activity.

[0038] Figure 3 The target compounds have inhibitory activity against sensitive and resistant breast cancer cell lines.

[0039] Figure 4 The target compound has an inhibitory activity against sensitive and resistant non-small cell lung cancer cell lines.

[0040] Figure 5 Effect of ferroptosis inhibitors on the antitumor activity of target compound 6o.

[0041] Figure 6 Effect of target compound 6o on intracellular ROS levels.

[0042] Figure 7Effect of target compound 6o on intracellular MDA levels.

[0043] Figure 8 Compound 6o promotes apoptosis of A549 and A549 / CDDP cells. DETAILED DESCRIPTION

[0044] The following implementation methods will help to understand the present invention, but are not limited to the contents of the present invention.

[0045] Example 1

[0046] Synthesis of compounds 3a-s in formula 1

[0047] 60% sodium hydride (NaH, 1.1 g, 27.66 mmol, 1.2 equiv.) was placed in a reaction flask, vacuumed, and replaced with nitrogen protection; anhydrous tetrahydrofuran (THF, 15 mL) was added, the reaction flask was placed in an ice bath, the reaction solution was stirred, and ethyl acetoacetate (3 g, 23.04 mmol, 1.0 equiv.) was slowly added, and a large number of bubbles were generated. After the bubbles disappeared, benzyl bromide with different substituents (2a-s, 27.66 mmol, 1.2 equiv.) was slowly added dropwise, the ice bath was removed, the temperature was gradually increased to 60°C, and the reaction was continued. At this time, the reaction solution was a white suspension system, and the reaction was monitored by TLC (PE: EA = 6: 1). The reaction was complete in 2.5-5 hours. Most of the dichloromethane was evaporated with a rotary evaporator, and a saturated ammonium chloride solution was added to adjust the pH value of the reaction solution to neutral; the reaction solution was extracted with ethyl acetate three times, a small amount of anhydrous sodium sulfate was added, and it was allowed to stand for 15 min; the organic phase was concentrated by rotary evaporation under reduced pressure to obtain an oil (3a-s). The crude product obtained by the reaction did not need to be purified and was directly used for the next reaction.

[0048] Example 2

[0049] Synthesis of compounds 4a-s in formula 1

[0050] The crude product (3a-s) obtained in the previous step and resorcinol (2.54 g, 23.04 mmol, 1.0 equiv.) were placed in a reaction bottle, and 70% sulfuric acid (100 mL) was slowly added under an ice bath; the ice bath was removed after stirring for 15 min, and the reaction was monitored by TLC (PE:EA=4:1), and the reaction was complete in 1-2 h; ice water (500 mL) was added to a beaker, and the reaction solution was slowly added under stirring, and solids precipitated; stirring was continued for 1 h, and the solids were filtered and washed with ice water, and dried to obtain a crude product; if it still cannot be loosened after stirring for a certain period of time, it is necessary to extract with ethyl acetate three times, add a small amount of anhydrous sodium sulfate, and stand for 15 min; the organic phase was concentrated by rotary evaporation under reduced pressure to obtain a solid crude product; the crude product was recrystallized from 1,2-dichloroethane to obtain the product (4a-s).

[0051] Example 3

[0052] Synthesis of compounds 5a-s in formula 1

[0053] Compound 4a-s (3.32mmol, 1.0equiv.), potassium carbonate (1.4g, 9.97mmol, 3.0equiv.), sodium iodide (0.26g, 1.7mmol, 0.5equiv.) and DMF (8mL) solution were placed in a reaction bottle, stirred and bromoethanol (1.15mL, 16.62mmol, 5.0equiv.) was slowly added dropwise to the reaction solution. The temperature was raised to 90°C, and the reaction was monitored by TLC (PE:EA=3:1). The reaction was basically complete in 12-15h. Ice water (150mL) was added to the beaker, and the reaction solution was slowly added under stirring, and solids precipitated; the reaction solution was filtered, the solids were washed with ice water, and the crude product was obtained after drying. After purification by column chromatography (PE:EA=5:1), the product (5a-s) was obtained.

[0054] Example 4

[0055] Synthesis of compounds 6a-s in formula 1

[0056] Compound 5a-s (0.81 mmol, 1.0 equiv.) and 3,4-dibenzenesulfonyl-1,2,5-oxadiazole-N-oxide (320 mg, 0.89 mmol, 1.1 equiv.) were placed in a reaction bottle, evacuated, and replaced with nitrogen protection; the reaction bottle was placed in an ice bath, and anhydrous dichloromethane (dry DCM, 10 mL) was added and stirred; DBU (270 μL, 1.80 mmol, 2.0 equiv.) was slowly added dropwise and stirred; the ice bath was removed, and TLC monitoring (DCM: MeOH = 50: 1) was performed. The reaction was basically completed in 16-20 hours; dichloromethane was extracted three times, a small amount of anhydrous sodium sulfate was added, and the mixture was allowed to stand for 15 min; the organic phase was concentrated by rotary evaporation under reduced pressure to obtain a solid crude product, which was purified by column chromatography (DCM: MeOH = 80: 1) to obtain the target compound 6a-s.

[0057] 6a (4-(2-((3-(2-methoxybenzyl)-4-methyl-2-oxo-2H-chromen-7-yl)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide): yield 65%; 1 H NMR (400 MHz, DMSO-d 6)δ7.97(d,J=7.9Hz,2H),7.87–7.79(m,1H),7.76(d,J=8.7Hz,1H),7.72 –7.61(m,2H),7.24–7.14(m,1H),7.08(s,1H),7.02(d,J=8.8Hz,1H),6.9 7(d,J=7.9Hz,1H),6.90(d,J=6.2Hz,1H),6.80(d,J=7.0Hz,1H),4.77(d, J=5.9Hz,2H),4.56–4.46(m,2H),3.85(s,2H),3.82(s,3H),2.35(s,3H). 13 C NMR (150MHz, DMSO) δ160.90,160.19,158.62,156.70,153.22,148.57,137.02,135.93,129.78,128.11,127.77,127.19,126. 47,126.31,120.32,120.08,113.87,112.35,110.37,101.07,69.57,65.90,55.15,54.74,26.38,14.88.HRMS(ESI)m / z:calcd forC 28 H 25 N 2 O 9 S + [M+H] + 565.1275, found 565.1266.

[0058] 6b (4-(2-((3-(3-methoxybenzyl)-4-methyl-2-oxo-2H-chromen-7-oxy)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide): yield 68%; 1 H NMR (400 MHz, DMSO-d 6 )δ7.97(d,J=7.9Hz,2H),7.85–7.79(m,1H),7.77(d,J=8.8Hz,1H),7.69–7.63(m,2H),7.20–7.14(m,1H),7.08(s,1H), 7.02(d,J=8.8Hz,1H),6.81–6.73(m,3H),4.80–4.73(m,2H),4.52–4.46(m,2H),3.93(s,2H),3.70(s,3H),2.44(s,3H). 13C NMR (150MHz, DMSO) δ161.07,160.26,159.17,158.61,153.18,148.24,140.67,137.01,135.93,129.77,129.29,128.1 0,126.60,121.03,120.01,112.40,111.11,110.37,101.08,69.56,65.91,54.73,31.97,15.05.HRMS(ESI)m / z:calcd for C 28 H 25 N 2 O 9 S + [M+H] + 565.1275, found 565.1252.

[0059] 6c (4-(2-((3-(4-methoxybenzyl)-4-methyl-2-oxo-2H-chromen-7-oxy)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide): yield 60%; 1 H NMR (400 MHz, DMSO-d 6 )δ8.00–7.93(m,2H),7.81(d,J=7.7Hz,1H),7.76(d,J=8.6Hz,1H),7.66(d,J=8.1Hz,2H),7.14(d,J=8.0Hz,2H),7.07(s,1 H),7.02(d,J=8.1Hz,1H),6.86–6.79(m,2H),4.80–4.71(m,2H),4.53–4.45(m,2H),3.87(s,2H),3.69(s,3H),2.44(s,3H). 13 C NMR (150MHz, DMSO) δ161.67,160.83,159.25,158.09,153.76,148.41,137.64,136.57,131.59,130.41,129.51,128.74, 127.19,122.26,114.31,113.02,111.01,101.69,70.20,66.54,55.45,49.07,31.74,19.03,15.63.HRMS(ESI)m / z:calcd for C 28 H 25 N 2 O 9 S + [M+H] +565.1275, found 565.1253.

[0060] 6d (4-(2-((3-(3,5-dimethoxybenzyl)-4-methyl-2-oxo-2H-chromen-7-oxy)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide): yield 64%; 1 H NMR(400MHz,Chloroform-d)δ8.03(d,J=7.5Hz,2H),7.77–7.70(m,1H),7.60–7.53(m,3H),6.91(d,J=8.7Hz,1H),6 .84(s,1H),6.43(s,2H),6.29(s,1H),4.85–4.75(m,2H),4.51–4.39(m,2H),3.99(s,2H),3.75(s,6H),2.43(s,3H). 13 C NMR (150 MHz, CDCl 3 )δ161.48,160.27,159.73,158.08,153.23,147.20,140.77,137.40,135.06,129.04,127.94,125.36,121.6 8,114.28,111.57,109.75,105.88,101.00,97.38,68.48,65.03,54.66,32.39,14.83.HRMS(ESI)m / z:calcd forC 29 H 27 N 2 O 10 S + [M+H] + 595.138, found 595.1355.

[0061] 6e (4-(2-((3-(3,4,5-trimethoxybenzyl)-4-methyl-2-oxo-2H-chromen-7-oxy)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide): yield 58%; 1 H NMR(400MHz,Chloroform-d)δ8.02(d,J=7.9Hz,2H),7.72(t,J=7.3Hz,1H),7.62–7.53(m,3H),6.93(d,J=9.0Hz,1H), 6.85(s,1H),6.51(s,2H),4.82–4.79(m,2H),4.47–4.42(m,2H),3.98(s,2H),3.81(s,6H),3.80(s,3H),2.47(s,3H).13 C NMR (150 MHz, CDCl 3 )δ161.57,159.80,158.08,153.20,152.64,146.96,137.37,136.02,135.06,134.19,129.04,127.94,125.38,1 21.94,114.22,111.67,109.76,104.89,101.04,68.49,65.07,60.20,55.55,32.52,14.86.HRMS(ESI)m / z:calcd for C 30 H 29 N 2 O 11 S + [M+H] + 625.1487, found 625.1464.

[0062] 6f (4-(2-((3-(2-trifluoromethylbenzyl)-4-methyl-2-oxo-2H-chromen-7-oxy)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide): yield 62%; 1 H NMR(400MHz,Chloroform-d)δ8.04(d,J=7.3Hz,2H),7.79–7.71(m,1H),7.69(d,J=7.6Hz,1H),7.65–7.55(m,3H),7.37(d,J=7.6Hz,1H),7.33– 7.27(m,1H),7.03(d,J=7.6Hz,1H),6.95(d,J=8.7Hz,1H),6.91(s,1H), 4.82(t,J=4.4Hz,2H), 4.48(t,J=4.5Hz,2H), 4.26(s,2H), 2.30(s,3H). 13 C NMR (150 MHz, CDCl 3 )δ161.41,160.04,158.10,153.53,148.76,137.39,136.71,135.08,131.44,129.06,127.96,127.49,125.69,125.5 6,125.52,125.44,120.21,114.07,111.79,109.77,101.14,68.47,65.11,52.80,28.47,14.65.HRMS(ESI)m / z:calcd for C 28 H 22 F 3 N2 O 8 S + [M+H] + 603.1043, found 603.1039.

[0063] 6 g (4-(2-((3-(3-trifluoromethylbenzyl)-4-methyl-2-oxo-2H-chromene-7-oxy)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide): yield 72%; 1 H NMR(400MHz,Chloroform-d)δ8.03(d,J=7.8Hz,2H),7.73(t,J=6.8Hz,1H),7.63–7.53(m,3H),7.53–7.50(m,1H),7.46(d,J=5.8H z,2H),7.39(d,J=7.7Hz,1H),6.94(d,J=8.9Hz,1H),6.86(s,1H),4.85–4.76(m,2H),4.48–4.43(m,2H),4.10(s,2H),2.45(s,3H). 13 C NMR (150 MHz, CDCl 3 )δ161.31,159.94,158.08,153.31,147.35,139.36,137.38,135.06,131.11,129.04,128.41,127.95,125.47,124.32 ,124.29,122.69,122.67,121.14,114.05,111.77,109.76,101.08,68.46,65.08,32.14,14.88.HRMS(ESI)m / z:calcd for C 28 H 22 F 3 N 2 O 8 S + [M+H] + 603.1043, found 603.1037.

[0064] 6h (4-(2-((3-(3,5-ditrifluoromethylbenzyl)-4-methyl-2-oxo-2H-chromen-7-oxy)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide): yield 66%; 1H NMR(400MHz,Chloroform-d)δ8.03(d,J=8.1Hz,2H),7.76–7.69(m,4H),7.62(d,J=8.9Hz,1H),7.60–7.54(m, 2H), 6.96 (d, J = 9.2Hz, 1H), 6.87 (s, 1H), 4.86–4.77 (m, 2H), 4.46 (t, J = 4.7Hz, 2H), 4.15 (s, 2H), 2.48 (s, 3H). 13 C NMR (150 MHz, CDCl 3 )δ161.13,160.20,158.08,153.39,147.81,140.94,137.37,135.06,131.28,131.07,129.04,127.95,127.84,125.61,12 3.56,121.75,120.14,119.97,113.81,111.99,109.77,101.15,68.42,65.13,52.80,32.15,14.96.HRMS(ESI)m / z:calcd for C 29 H 21 F 6 N 2 O 8 S + [M+H] + 671.0917, found 671.0907.

[0065] 6i (4-(2-((3-(4-bromobenzyl)-4-methyl-2-oxo-2H-chromen-7-yl)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide): yield 57%; 1 H NMR (400 MHz, Pyridine-d 5 )δ8.27(d,J=7.0Hz,2H),7.65–7.61(m,2H),7.55–7.48(m,4H),7.32(d,J=8.1Hz,2H) ,7.14–7.08(m,2H),4.95–4.89(m,2H),4.61–4.56(m,2H),4.03(s,2H),2.32(s,3H). 13C NMR(150MHz,Pyr)δ161.01,160.28,158.63,153.49,147.35,131.02,129.90,129.22 ,128.05,125.93,111.93,101.00,69.11,65.62,31.68,14.35.HRMS(ESI)m / z:calcd for C 27 H 22 Bn 2 O 8 S + [M+H] + 613.0275, found 613.0265.

[0066] 6j (4-(2-((3-(2-chlorobenzyl)-4-methyl-2-oxo-2H-chromen-7-yl)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide): yield 72%; 1 H NMR (400 MHz, DMSO-d 6 )δ7.98(d,J=7.8Hz,2H),7.88–7.79(m,2H),7.72–7.63(m,2H),7.47(d,J=8.9Hz,1H),7.29–7.17(m,2H),7.12(s, 1H),7.05(d,J=9.4Hz,1H),7.00(d,J=7.3Hz,1H),4.82–4.74(m,2H),4.56–4.47(m,2H),4.00(s,2H),2.37(s,3H). 13 C NMR (150MHz, DMSO) δ160.82,160.43,158.62,153.39,149.56,137.01,135.96,132.87,129.80,129.09,128.43,128.1 2,127.80,127.19,126.70,119.23,113.73,112.49,110.38,101.16,69.56,65.95,29.87,15.07.HRMS(ESI)m / z:calcd forC 27 H 22 C1N 2 O 8 S + [M+H] + 569.0780, found 569.0752.

[0067] 6k (4-(2-((3-(3-chlorobenzyl)-4-methyl-2-oxo-2H-chromen-7-yl)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide): yield 55%; 1 H NMR (400 MHz, DMSO-d 6 )δ7.97(d,J=7.9Hz,2H),7.85–7.80(m,1H),7.78(d,J=9.0Hz,1H),7.69–7.63(m,2H),7.34–7.27(m,2H),7.25(d,J=8.0Hz,1H ),7.19(d,J=7.5Hz,1H),7.09(s,1H),7.03(d,J=8.8Hz,1H),4.81–4.73(m,2H),4.55–4.46(m,2H),3.97(s,2H),2.46(s,3H). 13 C NMR (150MHz, DMSO) δ161.02,160.36,158.61,153.24,148.67,141.76,137.01,135.94,132.86,130.11,129.78,128.11,12 7.71,126.72,126.60,125.99,120.46,113.75,112.46,110.37,101.10,69.55,65.93,31.69,15.09.HRMS(ESI)m / z:calcd for C 27 H 22 C1N 2 O 8 S + [M+H] + 569.0780, found 569.0754.

[0068] 6l (4-(2-((3-(4-chlorobenzyl)-4-methyl-2-oxo-2H-chromen-7-oxy)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide): yield 59%; 1 H NMR (400 MHz, Pyridine-d 5 )δ8.26(d,J=7.8Hz,2H),7.62(d,J=7.5Hz,2H),7.55–7.48(m,2H),7.39–7.35(m,4H),7 .10(d,J=11.0Hz,2H),4.94–4.88(m,2H),4.61–4.55(m,2H),4.05(s,2H),2.32(s,3H). 13C NMR(150MHz,Pyr)δ162.53,161.78,160.14,155.00,148.85,139.48,139.20,136.69,132.69,131.03,130.73 ,129.57,127.43,122.79,115.51,113.44,111.96,102.51,70.62,67.13,33.13,15.86.HRMS(ESI)m / z:calcd for C 27 H 22 C1N 2 O 8 S + [M+H] + 569.0780, found 569.0751.

[0069] 6m (4-(2-((3-(3,4-dichlorobenzyl)-4-methyl-2-oxo-2H-chromen-7-oxy)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide): yield 54%; 1 H NMR (400 MHz, DMSO-d 6 )δ7.97(d,J=8.0Hz,2H),7.81(dd,J=19.1,8.1Hz,2H),7.69–7.63(m,2H),7.52(d,J=8.7Hz,2H),7.22(d,J=8. 4Hz,1H),7.09(s,1H),7.03(d,J=9.0Hz,1H),4.82–4.71(m,2H),4.55–4.45(m,2H),3.96(s,2H),2.46(s,3H). 13 C NMR (150MHz, DMSO) δ161.00,160.40,158.61,153.27,148.91,140.48,137.00,135.94,130.74,130.35,129.91,129.78,128 .56,128.31,128.11,126.77,120.13,113.74,112.49,110.37,101.10,69.54,65.94,31.20,15.10.HRMS(ESI)m / z:calcdfor C 27 H 21 Cl 2 N 2 O 8 S + [M+H] + 603.0390, found 603.0365.

[0070] 6n(4-(2-((3-(2,6-dichlorobenzyl)-4-methyl-2-oxo-2H-chromen-7-yl)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide): yield 61%; 1 H NMR (400 MHz, DMSO-d 6 )δ7.96(d,J=9.1Hz,2H),7.85–7.79(m,1H),7.76(d,J=9.1Hz,1H),7.69–7.61(m,2H),7.43(d,J=8.0Hz,2H),7.31 –7.24(m,1H),7.06(s,1H),7.00(d,J=8.9Hz,1H),4.82–4.71(m,2H),4.52–4.44(m,2H),4.23(s,2H),2.37(s,3H). 13 C NMR (150MHz, DMSO) δ160.22,159.89,158.61,153.10,148.08,137.02,135.91,135.05,134.94,129.77,128.62,12 8.48,128.10,126.58,119.49,113.72,112.43,110.37,100.96,69.55,65.90,29.22,14.99.HRMS(ESI)m / z:calcd forC 27 H 21 Cl 2 N 2 O 8 S + [M+H] + 603.0390, found 603.0363.

[0071] 6o(4-(2-((3-(3,5-dichlorobenzyl)-4-methyl-2-oxo-2H-chromen-7-oxy)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide): yield 57%; 1 H NMR (400 MHz, DMSO-d 6 )δ7.97(d,J=8.2Hz,2H),7.81(dd,J=18.5,8.3Hz,2H),7.71–7.63(m,2H),7.43(s,1H),7.29(s,2H), 7.09(s,1H),7.04(d,J=8.6Hz,1H),4.81–4.74(m,2H),4.53–4.46(m,2H),3.96(s,2H),2.46(s,3H).13 C NMR (150MHz, DMSO) δ161.03,160.44,158.61,153.31,149.18,143.63,137.01,135.94,133.81,129.78,128.11,12 6.82,126.70,125.76,119.75,113.74,112.49,110.37,101.11,69.54,65.94,31.53,15.12.HRMS(ESI)m / z:calcd for C 27 H 21 Cl 2 N 2 O 8 S + [M+H] + 603.0390, found 603.0354.

[0072] 6p(4-(2-((3-(3-cyanobenzyl)-4-methyl-2-oxo-2H-chromen-7-yl)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide): yield 61%; 1 H NMR (400 MHz, DMSO-d 6 )δ7.97(d,J=6.6Hz,2H),7.84(d,J=7.7Hz,1H),7.80(d,J=10.9Hz,1H),7.70(s,1H),7.69–7.63(m,3H),7.59(d,J=7.8Hz,1 H),7.53–7.46(m,1H),7.09(s,1H),7.03(d,J=8.5Hz,1H),4.80–4.74(m,2H),4.52–4.47(m,2H),4.01(s,2H),2.47(s,3H). 13 CNMR(150MHz,DMSO)δ161.00,160.37,158.61,153.30,148.96,140.90,137.00,135.94,133.01,131.39,129.91,129.79,129.4 7,128.11,126.78,120.09,118.69,113.80,112.44,111.21,110.37,101.09,69.54,65.94,31.67,15.12.HRMS(ESI)m / z:calcd for C 28 H 22 N 3 O 8 S + [M+H]+ 560.1122, found 560.1109.

[0073] 6q (4-(2-((3-(3-chloro-4-fluorobenzyl)-4-methyl-2-oxo-2H-chromen-7-yl)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide): yield 58%; 1 H NMR (400 MHz, DMSO-d 6 )δ7.97(d,J=8.5Hz,2H),7.86–7.80(m,1H),7.79(d,J=9.2Hz,1H),7.70–7.62(m,2H),7.44(d,J=7.2Hz,1H),7.34–7.27(m,1H),7. 23(d,J=4.8Hz,1H),7.09(s,1H),7.03(d,J=8.9Hz,1H),4.80–4.73(m,2H),4.53–4.45(m,2H),3.95(s,2H),2.46(d,J=2.4Hz,3H). 13 C NMR (150MHz, DMSO) δ161.01,160.37,158.61,156.43,154.80,153.25,148.74,137.11,137.00,135.94,129.78,128.47,128.43,128.1 1,126.75,120.42,119.07,118.95,116.65,116.52,113.76,112.47,110.37,101.10,69.55,65.93,31.05,15.07.HRMS(ESI)m / z:calcd forC 27 H 21 CIF 2 O 8 S + [M+H] + 587.0686, found 587.0683.

[0074] 6r (4-(2-((3-(4-chloro-3-fluorobenzyl)-4-methyl-2-oxo-2H-chromen-7-yl)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide): yield 67%; 1 H NMR (400 MHz, DMSO-d 6)δ7.97(d,J=7.8Hz,2H),7.86–7.81(m,1H),7.79(d,J=9.1Hz,1H),7.67(d,2H),7.44(d,J=7.3Hz,1H),7.34–7.27(m,1H) ,7.27–7.21(m,1H),7.09(s,1H),7.03(d,J=8.9Hz,1H),4.82–4.72(m,2H),4.55–4.45(m,2H),3.95(s,2H),2.46(s,3H). 13 C NMR (150MHz, DMSO) δ161.01,160.37,158.61,156.43,154.81,153.26,148.74,137.10,137.00,135.94,129.78,128.48,128.43,128.1 1,126.75,120.42,119.07,118.96,116.66,116.52,113.76,112.47,110.37,101.10,69.55,65.93,31.05,15.07.HRMS(ESI)m / z:calcd for C 27 H 21 CIF 2 O 8 S + [M+H] + 587.0686,found587.0676.

[0075] 6s (4-(2-((3-(3-chloro-5-fluorobenzyl)-4-methyl-2-oxo-2H-chromen-7-yl)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide): yield 55%; 1 H NMR(400MHz,Chloroform-d)δ7.54(d,J=8.9Hz,1H),7.02(s,1H),6.95–6.87(m,2 H),6.85(s,1H),4.17–4.12(m,2H),4.02(s,2H),3.99-3.92(m,2H),2.41(s,3H). 13C NMR (150MHz, DMSO) δ161.01,160.37,158.61,156.43,154.81,153.26,148.74,137.10,137.00,135.94,129.78,128.48,128.43,128.1 1,126.75,120.42,119.07,118.96,116.66,116.52,113.76,112.47,110.37,101.10,69.55,65.93,31.05,15.07.HRMS(ESI)m / z:calcd for C 27 H 21 CIF 2 O 8 S + [M+H] + 587.0686,found587.0678.

[0076] Example 5

[0077] Synthesis of compounds 7a-d in formula 2

[0078] The reaction operation and feed ratio are the same as those in the synthesis of compounds (3a-s). The crude products (7a-d) obtained by the reaction do not need to be purified and are directly used for the next reaction.

[0079] Example 6

[0080] Synthesis of compounds 8a-d in formula 2

[0081] The reaction operation and feed ratio are the same as those in the synthesis of compound (4a-s). The crude product is purified by column chromatography (PE:EA=4:1) to obtain product (8a-d).

[0082] Example 7

[0083] Synthesis of compounds 9a-d in formula 2

[0084] The reaction operation and feed ratio are the same as those in the synthesis of compound (5a-s). The crude product is purified by column chromatography (PE:EA=5:1) to obtain product (9a-d).

[0085] Example 8

[0086] Synthesis of compounds 10a-d in formula 2

[0087] 9a-d (7.04 mmol, 1.0 equiv.) and SnCl 2 ·2H 2O (6.4 g, 28.14 mmol, 4.0 equiv.) and DMF (15 mL) were placed in a reaction bottle and reacted overnight at room temperature. The reaction was monitored by TLC (DCM: MeOH = 80: 1). After 14 hours, the reaction was almost complete. After the reaction was completed, saturated NaHCO 3 Solution, adjust the pH of the reaction solution to weak alkalinity, bubbles are generated when adding dropwise, white solids are continuously precipitated in the reaction solution, the reaction solution is filtered, the solids are washed with ice water for many times, and a white crude product is obtained after drying. If the reaction product is in a colloid state and cannot be dried directly, extract it with ethyl acetate three times, add a small amount of anhydrous sodium sulfate, and let it stand for 15 minutes; the organic phase is concentrated by vacuum rotary evaporation to obtain a solid crude product, which is purified by column chromatography (DCM: MeOH = 100: 1) to obtain products 10a-d.

[0088] Example 9

[0089] Synthesis of compounds 11a-d in formula 2

[0090] 10a-d (1.55 mmol, 1.0 equiv.) was placed in a reaction bottle, and dichloromethane (15 mL) was added to dissolve, and triethylamine (225 μL, 1.55 mmol, 1.0 equiv.) and di-tert-butyl carbonic anhydride (470 μL, 2.01 mmol, 1.3 equiv.) were added. The temperature was raised to 60°C, and the reaction was stirred overnight. The reaction was monitored by TLC (DCM: MeOH = 50: 1). The reaction was basically completed after 17 hours. Most of the dichloromethane was evaporated by rotary evaporator, and saturated ammonium chloride solution was slowly added dropwise to adjust the pH value of the reaction solution to neutral. It was extracted with ethyl acetate three times, and a small amount of anhydrous sodium sulfate was added and allowed to stand for 15 min. The organic phase was concentrated by rotary evaporation under reduced pressure to obtain a solid crude product. After purification by column chromatography (DCM: MeOH = 80: 1), the product 11a-d was obtained.

[0091] Example 10

[0092] Synthesis of compounds 12a-d in formula 2

[0093] The reaction operation and feed ratio are the same as those in the synthesis of compounds (6a-s). The crude products (12a-d) obtained from the reaction are directly used for the next step without further purification.

[0094] Embodiment 11

[0095] Synthesis of compounds 13a-d in formula 2

[0096] 12a-d (0.07 mmol, 1.0 equiv.) was placed in a reaction bottle, 20% trifluoroacetic acid (TFA, 10 mL) was added to dissolve and stirred, and the reaction was carried out at room temperature. The reaction was monitored by TLC (DCM: MeOH = 50: 1). The reaction was almost complete in 1.5-2 h. Saturated NaHCO was slowly added dropwise 3 solution, adjust the pH value of the reaction solution to neutral; extract with ethyl acetate three times, add a small amount of anhydrous sodium sulfate, and stand for 15 minutes; concentrate the organic phase by rotary evaporation under reduced pressure to obtain a solid crude product; and purify by column chromatography (DCM: MeOH = 80: 1) to obtain the product 13a-d.

[0097] 13a (4-(2-((3-(2-aminobenzyl)-4-methyl-2-oxo-2H-chromen-7-yl)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide): yield 49%; 1 HNMR (600 MHz, DMSO-d 6 )δ7.97(d,J=6.8Hz,2H),7.86–7.82(m,1H),7.78(d,J=8.9Hz,1H),7.70–7.63(m,2H),7.10(s,1H),7.03(d,J=8.8Hz,1H),6.92–6.87(m,1H), 6.67(d,J=8.0Hz,1H),6.59(d,J=7.6Hz,1H),6.44–6.40(m,1H),5.06( s,2H),4.81–4.76(m,2H),4.56–4.50(m,2H),3.69(s,2H),2.33(s,3H). 13 CNMR(150MHz,DMSO)δ161.89,160.91,159.25,153.86,149.72,146.71,137.66,136.58,130.43,128.74,127.10,1 22.31,120.85,116.69,115.11,114.50,113.09,111.02,101.76,70.21,66.56,28.10,15.63.HRMS(ESI)m / z:calcd for C 27 H 24 N 3 O 8 S + [M+H] + 550.1279, found 550.1255.

[0098] 13b (4-(2-((3-(3-aminobenzyl)-4-methyl-2-oxo-2H-chromen-7-yl)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide): yield 58%; 1 H NMR (600 MHz, DMSO-d 6 )δ7.98(d,J=7.8Hz,2H),7.86–7.81(m,1H),7.77(d,J=8.8Hz,1H),7.69–7.63(m,2H),7.07(s,1H),7.02(d,J=9.1Hz,1H),6.9 4–6.88(m,1H),6.42(s,1H),6.41–6.37(m,2H),5.17(s,2H),4.80–4.75(m,2H),4.55–4.46(m,2H),3.81(s,2H),2.42(s,3H). 13 C NMR (150MHz, DMSO) δ161.68,160.82,159.25,153.78,148.71,148.55,140.21,137.64,136.58,130.42,129.33,128.74,12 7.15,122.06,116.51,114.51,114.06,113.00,112.54,111.01,101.70,70.19,66.55,32.65,15.68.HRMS(ESI)m / z:calcd for C 27 H 24 N 3 O 8 S + [M+H] + 550.1279, found 550.1268.

[0099] 13c (4-(2-((3-(4-aminobenzyl)-4-methyl-2-oxo-2H-chromen-7-yl)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide): yield 55%; 1 H NMR(400MHz,Chloroform-d)δ8.02(d,J=7.6Hz,2H),7.75–7.68(m,1H),7.60–7.51(m,3H),7.07(d,J=7.3Hz,2H) ,6.90(d,J=8.8Hz,1H),6.83(s,1H),6.61(d,J=6.9Hz,2H),4.79(s,2H),4.42(s,2H),3.92(s,2H),2.43(s,3H). 13C NMR (150 MHz, CDCl 3 )δ161.53,159.57,158.09,153.13,146.39,143.94,137.38,135.07,129.04,128.57,128.46,127.93,12 5.28,122.73,114.80,114.40,111.49,109.75,100.95,68.50,65.02,31.40,14.75.HRMS(ESI)m / z:calcd for C 27 H 24 N 3 O 8 S + [M+H] + 550.1279, found 550.1271.

[0100] 13d (4-(2-((3-(4-aminophenethyl)-4-methyl-2-oxo-2H-chromene-7-oxy)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide): yield 60%; 1 H NMR (600 MHz, DMSO-d 6 )δ7.98(d,J=7.9Hz,2H),7.86–7.79(m,1H),7.69(d,J=8.6Hz,1H),7.68–7.64(m,2H),7.04(s,1H),6.98(d,J=8.8Hz,1H),6.84(d,J=8. 4Hz,2H),6.47(d,J=8.5Hz,2H),4.98(s,2H),4.77(s,2H),4.54–4.45(m,2H),2.74(t,J=7.8Hz,2H),2.58(t,J=8.0Hz,2H),2.19(s,3H). 13 C NMR (150MHz, DMSO) δ161.31,160.56,159.26,153.60,147.71,146.77,137.66,136.57,130.42,129.35,128.74,1 26.98,122.36,114.57,114.47,112.86,111.01,101.67,70.19,66.50,33.71,30.17,14.99.HRMS(ESI)m / z:calcd for C 28 H 26 N 3 O 8 S + [M+H] +564.1435, found 564.1422.

[0101] Example 12

[0102] Synthesis of compounds 15a-d in formula 3

[0103] The reaction operation and feed ratio are the same as those in the synthesis of compounds (3a-s). The crude products (15a-d) obtained by the reaction do not need to be purified and are directly used for the next reaction.

[0104] Embodiment 13

[0105] Synthesis of compounds 16a-d in formula 3

[0106] The reaction operation and feed ratio are the same as those in the synthesis of compound (4a-s). The crude product is recrystallized from ethanol to obtain product (16a-d).

[0107] Embodiment 14

[0108] Synthesis of compounds 17a-d in formula 3

[0109] The reaction operation and feed ratio were the same as those in the synthesis of compound (5a-s). The crude product was purified by column chromatography (PE:EA=3:1) to obtain product (17a-d).

[0110] Embodiment 15

[0111] Synthesis of compounds 18a-d in formula 3

[0112] The reaction operation and feed ratio were the same as those for the synthesis of compound (6a-s). The crude product was purified by column chromatography (DCM:PE=3:1) to obtain product (18a-d).

[0113] 18a (4-(2-((3-(3-chloro-4-fluorobenzyl)-4-ethyl-2-oxo-2H-chromen-7-oxy)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide): yield 58%; 1 H NMR (400 MHz, DMSO-d 6)δ7.97(d,J=7.7Hz,2H),7.86–7.82(m,1H),7.80(d,J=9.2Hz,1H),7.67(d,J=7.7Hz,2H),7.46(d,J=7.3Hz,1H),7.35–7.27(m,1H),7.28–7. 20(m,1H),7.11(s,1H),7.04(d,J=8.9Hz,1H),4.83–4.70(m,2H),4.56–4.46(m,2H),3.94(s,2H),2.96–2.82(m,2H),1.07(t,J=6.7Hz,3H). 13 C NMR (150MHz, DMSO) δ161.94,160.96,159.25,157.05,155.43,154.55,15 4.46,137.97,137.95,137.66,136.56,130.42,129.00,128.96,128.73, 127.16,120.22,119.70,119.59,117.29,117.15,113.29,113.04,111.0 1,102.06,70.19,66.56,31.27,22.08,14.04,0.57.HRMS(ESI)m / z:calcd for C 28 H 23 CIF 2 O 8 S + [M+H] + 601.0842, found 601.0808.

[0114] 18b (4-(2-((3-(3-chloro-4-fluorobenzyl)-4-n-propyl-2-oxo-2H-chromen-7-oxy)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide): yield 56%; 1 H NMR (400 MHz, DMSO-d 6)δ7.96(d,J=8.7Hz,2H),7.86–7.75(m,2H),7.70–7.62(m,2H),7.46(d,J=6.5Hz,1H),7.34–7.27(m,1H),7.24(d,J=4.9Hz,1H),7.10(s,1H) ,7.03(d,J=8.8Hz,1H),4.83–4.72(m,2H),4.56–4.46(m,2H),3.94(s,2H),2.84(t,J=8.0Hz,2H),1.46–1.34(m,2H),0.99(t,J=7.2Hz,3H). 13 C NMR (150MHz, DMSO) δ161.90,160.94,159.25,157.04,155.42,154.36,153 .09,138.05,137.66,136.55,130.41,130.35,128.99,128.94,128.73,127 .30,120.66,119.68,119.56,117.28,117.14,113.38,113.29,111.01,101 .95,70.19,66.56,31.45,30.71,22.97,14.46,0.56.HRMS(ESI)m / z:calcd for C 29 H 25 CIF 2 O 8 S + [M+H] + 615.0999, found 615.0972.

[0115] 18c (4-(2-((3-(3-chloro-4-fluorobenzyl)-4-phenyl-2-oxo-2H-chromen-7-oxy)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide): yield 55%; 1 H NMR (400 MHz, DMSO-d 6)δ7.96(d,J=7.7Hz,2H),7.86–7.79(m,1H),7.71–7.63(m,2H),7.61–7.52(m,3H),7.32(d,J=7.8Hz,2H),7.23(d,J=9.0Hz,1H),7.19(s,1H), 7.16(d,J=6.9Hz,1H),7.03–6.98(m,1H),6.94(d,J=8.9Hz,1H),6.87(d,J=8.9Hz,1H),4.80–4.72(m,2H),4.49(d,J=5.5Hz,2H),3.62(s,2H). 13 C NMR (150MHz, DMSO) δ161.54,161.20,159.23,157.00,155.37,154.44,152.7 7,137.64,137.38,137.36,136.58,134.56,130.43,130.38,129.41,128.87 ,128.83,128.72,128.58,121.08,119.51,119.39,117.07,116.93,114.56, 113.37,110.99,101.92,101.75,70.15,66.67,32.83.HRMS(ESI)m / z:calcd for C 32 H 23 CIF 2 O 8 S + [M+H] + 649.0842, found 649.0806.

[0116] 18d (4-(2-((3-(3-chloro-4-fluorobenzyl)-4-(4-trifluoromethylphenyl)-2-oxo-2H-chromene-7-oxy)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide): yield 61%; 1 H NMR (600 MHz, DMSO-d 6 )δ8.02–7.90(m,4H),7.83(s,1H),7.67(s,2H),7.57(s,2H),7.28–7.19(m,2H),7.15(s,1H),7 .03(s,1H),6.93(s,1H),6.83(s,1H),4.83–4.68(m,2H),4.50(s,2H),3.62(t,J=11.5Hz,2H). 13 C NMR (150 MHz, CDCl 3)δ166.13,166.07,163.98,161.77,160.15,159.21,156.11,143.59,142.39,141.90,141.88,141.34,135.18,134.46,133.47,131.12 ,130.16,128.36,126.14,124.29,124.17,121.85,121.71,118.93,118.28,115.73,106.70,74.87,71.45,37.52.HRMS(ESI)m / z:calcd for C 33 H 22 CIF 4 N 2 O 8 S + [M+H] + 717.0716, found 717.0706.

[0117] Example 16

[0118] Synthesis of the compound 8-aldehyde-7-hydroxy-4-methyl-2H-chromen-2-one (20) in the general formula 4

[0119] First, 7-hydroxy-4-methylcoumarin (19.4 g, 22.70 mmol, 1.0 equiv.) and urotropine (16 g, 113.5 mmol, 5.0 equiv.) were placed in a reaction bottle, glacial acetic acid (50 mL) was added, and the temperature of the reaction solution was raised to 95 ° C. TLC monitored the reaction (PE: EA = 5: 1), and the first step of the reaction was basically completed after 18 hours. The reaction solution was naturally cooled to 70 ° C, and after adding 5N hydrochloric acid (50 mL), the reaction was continued for 1.5 hours, and TLC monitored the reaction (PE: EA = 5: 1). Ice water (500 mL) was added to the beaker, and the reaction solution was slowly added under stirring. A large amount of light yellow solid was precipitated, the solution was filtered, the solid was washed with ice water, and dried to obtain a light yellow crude product; if no solid was precipitated, the reaction solution can be treated with saturated NaHCO 3 Adjust to neutral, extract with ethyl acetate three times, add a small amount of anhydrous sodium sulfate, and stand for 15 minutes; the organic phase is concentrated by rotary evaporation under reduced pressure to obtain a solid crude product. The crude product 20 is purified by column chromatography (PE: EA = 6: 1) to obtain product 20 (1.62 g), with a yield of 35%.

[0120] Embodiment 17

[0121] Synthesis of the compound 8-aldehyde-7-isopropoxy-4-methyl-2H-chromen-2-one (21) in the general formula 4

[0122] Compound 20 (3 g, 14.7 mmol, 1.0 equiv.), potassium carbonate (6.1 g, 44.1 mmol, 3.0 equiv.) and sodium iodide (1.1 g, 7.4 mmol, 0.5 equiv.) were placed in a reaction bottle, DMF (15 mL) was added to dissolve and stirred, bromoethanol (5.08 mL, 73.5 mmol, 5.0 equiv.) was slowly added, and white smoke was generated; the temperature of the reaction solution was raised to 90 ° C, and the reaction was monitored by TLC (PE: EA = 2: 1). The reaction was basically complete in 14 hours. Ice water (200 mL) was added to a beaker, and the reaction solution was slowly added under stirring, and solids precipitated; the reaction solution was filtered, the solids were washed with ice water, and the crude product was obtained after drying. The crude product was purified by column chromatography (PE: EA = 5: 1) to obtain product 21 (2.91 g) with a yield of 80%.

[0123] Embodiment 18

[0124] Synthesis of the compound of formula 4 (4-(2-((8-formyl-4-methyl-2-oxo-2H-chromene-7-oxy)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide) (22)

[0125] Compound 21 (200 mg, 0.81 mmol, 1.0 equiv.) and 3,4-dibenzenesulfonyl-1,2,5-oxadiazole-N-oxide (320 mg, 0.89 mmol, 1.1 equiv.) were placed in a reaction bottle, vacuumed, and replaced with nitrogen protection; the reaction bottle was placed in ice water, and anhydrous dichloromethane (dry DCM, 10 mL) was added; DBU (270 μL, 1.80 mmol, 2.0 equiv.) was added dropwise to the reaction bottle and stirred; the ice bath was removed, and TLC monitoring (DCM: MeOH = 50: 1) was performed. The reaction was basically completed in 48 hours. Dichloromethane was extracted three times, a small amount of anhydrous sodium sulfate was added, and the mixture was allowed to stand for 15 minutes; the organic phase was concentrated by rotary evaporation under reduced pressure to obtain a solid crude product, which was purified by column chromatography (DCM: MeOH = 80: 1) to obtain product 22 (253 mg) with a yield of 66%.

[0126] Embodiment 19

[0127] Synthesis of the compound of formula 4 (4-(2-((8-hydroxymethyl-4-methyl-2-oxo-2H-chromene-7-oxy)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide) (23)

[0128] Compound 22 (200 mg, 0.42 mmol, 1.0 equiv.) was placed in a reaction bottle, placed in an ice bath, methanol (10 mL) was added and stirred for reaction. NaBH 4(25 mg, 0.63 mmol, 1.5 equiv.), bubbles are generated. Sodium borohydride should not be added too quickly, and the reaction is rapid. After the bubbles disappear, remove the ice bath, monitor by TLC (DCM: MeOH = 80: 1), and the reaction is complete in 3 hours. Add 100 mL of ice water to a beaker, slowly pour in the reaction solution and stir, adjust the pH value of the reaction solution to neutral with 2N hydrochloric acid, and a white solid precipitates. Filter the reaction solution, wash the filter cake with ice water, and dry to obtain a white crude product 23 (185.1 mg), which is directly used for the next step without purification.

[0129] Embodiment 20

[0130] Synthesis of the compound of formula (4-(2-((8-(3,4,5-trimethoxyphenylacetylmethyl)-4-methyl-2-oxo-2H-chromene-7-oxy)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide) (24)

[0131] 3,4,5-Trimethoxyphenylacetic acid (115 mg, 0.507 mmol, 3.0 equiv.), EDCI (130 mg, 0.676 mmol, 4.0 equiv.), DMAP (9 mg, 0.067 mmol, 0.4 equiv.) and dichloromethane (5 mL) solution were placed in a reaction bottle and reacted under ice bath for 0.5 h; raw alcohol 23 (80 mg, 0.169 mmol, 1.0 equiv.) was added and the reaction continued overnight at room temperature. TLC monitoring (DCM: MeOH = 80: 1) showed that the reaction was complete in 24 h. Extracted once with 2 mol / L hydrochloric acid solution, washed twice with water, added a small amount of anhydrous sodium sulfate, and allowed to stand for 15 min; the organic phase was concentrated by vacuum rotary evaporation to obtain a solid crude product. The crude product was purified by column chromatography (DCM: MeOH = 100: 1) to obtain product 24 (148.42 mg).

[0132] 24 ((4-(2-((8-(3,4,5-trimethoxyphenylacetylmethyl)-4-methyl-2-oxo-2H-chromene-7-oxy)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide)): yield 43%; 1H NMR(600MHz,Chloroform-d)δ8.01(d,J=7.9Hz,2H),7.72–7.69(m,1H),7.63(d,J=8.8Hz,1H),7.56–7.52(m,2H),6.95(d,J=8.7Hz,1H) ,6.46(s,2H),6.20(s,1H),5.43(s,2H),4.68–4.60(m,2H),4.42(t,J=5.7Hz,2H),3.80(s,3H),3.77(s,6H),3.52(s,2H),2.43(s,3H). 13 C NMR (150 MHz, CDCl 3 )δ170.51,167.15,159.69,158.90,158.10,152.93,152.45,151.64,137.13 ,136.26,135.05,130.26,129.03,127.98,125.77,114.06,112.22,111.67, 109.88,107.66,105.77,68.36,67.53,65.87,60.17,55.42,54.47,40.75,3 8.10,29.73,28.30,23.12,22.35,18.15,13.42,10.33.HRMS(ESI)m / z:calcd for C 32 H 31 N 2 O 13 S + [M+H] + 682.65, found 682.8.

[0133] Example 21 Anti-tumor activity test at the cell level

[0134] The MTS method was used to detect the activity of the compounds of the present invention in inhibiting tumor cell proliferation. Cancer cells in the logarithmic growth phase were inoculated in a 96-well plate and divided into a blank control group, a positive control group and different concentrations of the compounds of the present invention or positive drug treatment groups. After culturing at 37°C for 48 hours, MTT detection was performed to calculate the cell proliferation inhibition rate and IC 50 The results showed that most of the compounds of the present invention had an IC value of 0.04 for the growth inhibition of MCF-7 / ADR, A549, H1299, H2030, H1975, A549 / T and A549 / CDDP tumor cells. 50The values ​​were below 100 nM, which was significantly higher than the inhibitory activity on MCF-7 tumor cells. Among them, 4-(2-(3-(2-aminobenzyl)-4-methyl-2-oxo-2H-chromene-7-oxy)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole-2-oxide (13a), 4-(2-(3-(4-aminobenzyl)-4-methyl-2-oxo-2H-chromene-7-oxy)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole-2-oxide and 4-(2-(3-(3,5-dichlorobenzyl)-4-methyl-2-oxo-2H-chromene-7-oxy)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole-2-oxide, which had better inhibitory activity, had an IC value of 1. 50 The values ​​were 3.15, 4.42 and 6.31 nM, respectively, compared with the sensitive cell MCF-7 (IC 50 The antiproliferative activity of the lead compound CY-16S-4A93 (values ​​were 3262.51, 2733.15 and 2694.27 nM, respectively) was increased by 1065, 615 and 431 times, which was better than that of the lead compound CY-16S-4A93 (405 times) (see Table 1 and Figure 3 ). In addition, at a dosage concentration of 20 nM, most of the target compounds had good antiproliferative activity against six non-small cell lung cancer cell lines, and the target compounds had better proliferation inhibitory activity against sensitive non-small cell lung cancer cell lines (H1299, H2030, H1975 and A549) than against resistant strains (A549 / T and A549 / CDDP). Among them, 4-(2-(3-(3-chlorobenzyl)-4-methyl-2-oxo-2H-chromene-7-oxy)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole-2-oxide (6k), 4-(2-(3-(2,6-dichlorobenzyl)-4-methyl-2-oxo-2H-chromene-7-oxy)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole-2-oxide (6n), 4-(2-( 3-(2-chlorobenzyl)-4-methyl-2-oxo-2H-chromen-7-oxy)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole-2-oxide (6j) and 4-(2-(3-(3,5-dichlorobenzyl)-4-methyl-2-oxo-2H-chromen-7-oxy)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole-2-oxide (6o) showed significant effects on the 4 sensitive non-small cell lung cancer cell lines (IC 50 values ​​were 11.72-21.11 nM) and two drug-resistant cell lines (IC 50 The cell proliferation inhibition activity was optimal (see Table 2 and Figure 4 ).

[0135] Table 1 shows the antiproliferative activity of the target compounds (6c-e, 6o-p and 13a-d) against breast cancer sensitive cell lines and resistant cell lines.

[0136] Table 2 shows the antiproliferative activity of the target compounds (6a, 6g-h, 6j-k, 6n-o, 6q and 18a) against sensitive and resistant non-small cell lung cancer cell lines.

[0137] Table 3 shows the NO concentrations released by the compounds of the present invention (6a, 6g-h, 6j-k, 6n-o, 6q and 18a) in tumor cells.

[0138] Table 4 shows the solubility of the compounds of the present invention.

[0139] Table 1

[0140]

[0141] Table 2

[0142]

[0143]

[0144] Example 22 Intracellular NO release assay and the effect of NO scavengers on antitumor activity

[0145] (1) The classic Griess reagent was used to detect the intracellular NO release level of the compounds of the present invention. The A549 tumor cells (1×10 7 After incubating the cells with 100 μM of the compound of the present invention for 150 minutes (in a 10 cm dish), the cells were collected and lysed on ice with RIPA lysis buffer for 30 minutes, the cell lysate was centrifuged at 4°C and 12000 rpm for 15 minutes, NADPH, FAD, and Nitrate Reductase were added to the supernatant, and the cells were incubated at 37°C for 30 minutes; LDH and LDH Buffer were added, and the cells were incubated at 37°C for another 30 minutes; then the cells were mixed with Griess reagent for 30 minutes, and the absorbance was detected at 540 nm. Cells without drug action were treated under the same conditions as the background, and different concentrations of sodium nitrite were treated in the same way to prepare a standard curve, and the original active compound CY-16S-4A93 was used as a control. The results are shown in Table 3, and the compound of the present invention can release a considerable concentration of NO.

[0146] (2) The test cells were inoculated in a 96-well plate, and a zero adjustment group without cells was set up. The NO scavenger Hemoglobin (Beyotime) was diluted into 4 concentrations (final concentrations were 0, 6.25, 12.5 and 25 μM). The plate was placed in a 37°C incubator. After 24 hours, the test compound was added at a concentration of 50 nM. After incubation in the control group for 48 hours, the OD value at 490 nm was detected by an enzyme marker, and the inhibition rate was calculated according to the following formula:

[0147] Inhibition rate = [(OD 对照 -OD 给药 ) / (OD 对照 -OD 调零 )]×100%

[0148] The results showed that (see Figure 2 ), with the increase of the concentration of NO scavenger Hemoglobin, the inhibition rate of compound 6o on tumor cells A549 gradually decreased, showing a concentration-dependent relationship.

[0149] Table 3

[0150]

[0151]

[0152] Example 23 Determination of the effect of ferroptosis inhibitors on the proliferation inhibition activity of compounds in A549 and A549 / CDDP cells

[0153] A549 and A549 / CDDP cells were cultured, digested with 0.25% trypsin (Beyotime) for 1-2 minutes, centrifuged (1000r, 5min) and the cells were collected. The collected tumor cells were counted and inoculated into a sterile 96-well plate (about 6000-10000 cells per well). A blank group (no cells) was set up and placed in an incubator for culture. The ferroptosis inhibitor (Fer-1) was diluted to 4 concentrations (0, 2.5, 10 and 20 μM) with culture medium (final concentrations were 0, 1.25, 2.5, 5 and 10 μM). After culturing the 96-well plate in the incubator for 24 hours, 100 μL of different concentrations of Fer-1 were first added to the 96-well plate and 3 sub-wells were set up, and then an equal amount of 100 nM of compound 6o (final concentration was 50 nM) was added and mixed. The control group and the blank group only added culture medium. After incubation in the incubator for 48 hours, the culture medium in the wells was aspirated with a pipette, and an equal amount of 0.5 mg / mL thiazolyl blue solution was added to each well. The wells were placed in the incubator for 4 hours. The OD value at 570 nm was detected by a microplate reader, and the inhibition rate was calculated according to the following formula:

[0154] Proliferation inhibition rate (%) = [(OD 对照 –OD 给药) / (OD 对照 –OD 空白 )]×100

[0155] The results showed that (see Figure 5 ), with the increase of Fer-1 reagent concentration, the proliferation inhibition rate of compound 6o on A549 and A549 / CDDP cells gradually decreased, showing a concentration-dependent relationship. When the Fer-1 concentration was 300nM, the activity of A549 and A549 / CDDP cells was almost unaffected (cell survival rate was greater than 95%); when compound 6o was used alone, at a dosage concentration of 100nM, the proliferation inhibition rate of compound 6o on A549 and A549 / CDDP cells was greater than 80%. This result shows that the proliferation inhibition effect of coumarin-furoxan conjugate 6o on A549 and A549 / CDDP cells may be related to the induction of ferroptosis in tumor cells.

[0156] Example 24 Determination of intracellular reactive oxygen species (ROS) and lipid peroxide (MDA) levels

[0157] A549 and A549 / CDDP cells were cultured, digested with 0.25% trypsin (Beyotime) for 1-2 minutes, centrifuged (1500r, 3min) and collected. The collected tumor cells were counted, resuspended in 500μL of 1640 medium without phenol red and serum, and 500μL DCFH-DA fluorescent probe (10mmol / L) was added. After mixing, they were inoculated into 96-well plates and placed in an incubator for 20min. Compound 6o of different concentrations (15, 30 and 60nM) was added to the 96-well plate, and 3 sub-wells were set and mixed. The control group and the blank group were only added with culture medium and placed in an incubator for continued culture. After 3, 6, 9, and 12h of culture, the fluorescence intensity of each well was detected by BioTek multi-function microplate reader (using 488nm excitation wavelength and 525nm emission wavelength). The results of ROS-related experiments showed that compound 6o could produce ROS in A549 and A549 / CDDP cells. As the concentration of compound 6o increased, the relative level of ROS in A549 and A549 / CDDP cells gradually increased, with significant differences from the control group, showing a concentration-dependent manner (e.g. Figure 6 shown).

[0158] The required A549 and A549 / CDDP cells were cultured. When the tumor cells were growing well (3-6 generations), they were digested with 0.25% trypsin (Beyotime) for 1-2 minutes, centrifuged (1000r, 10 minutes) and the cells were collected. The collected A549 cells were inoculated into 6-well plates and placed in an incubator for 24 hours. 1 mL of the test compound 6o at different concentrations (20, 40 and 80 nM) was added to each dish, and the dish was placed in an incubator for 12 hours. After 12 hours, the drug-containing culture medium was aspirated, and the cells in the dish were washed several times with PBS. 200 μL of RIPA lysis buffer (Beyotime) was added to each dish and placed on ice for lysis for 30 minutes. Vortex, collect and centrifuge the cells, and take the supernatant in the centrifuge tube for use; take part of the supernatant and use the BCA protein concentration determination kit to determine the protein concentration; the standard in the kit was configured into 6 different concentrations (1, 2, 5, 10, 20, 50 μM) for use. According to the requirements of the kit, appropriate reagents were added to the 6-well plate, and 3 sub-wells were set for each group of the test compound 6o group, blank group and standard group; after mixing, it was placed in a boiling water bath and heated for 15 minutes. Cool to room temperature, centrifuge (1000r, 5min), take 200μL of the supernatant, and use an enzyme reader to detect the OD value of 532nm. The intracellular MDA level was calculated based on the protein concentration and the standard curve. The results of MDA-related experiments showed that compound 6o could induce the accumulation of lipid peroxide malondialdehyde (MDA) in A549 and A549 / CDDP cells. With the increase of the drug concentration of compound 6o, the relative level of MDA in A549 cells increased from 1.00 to 2.03, and the relative level of MDA in A549 / CDDP cells increased from 1.00 to 4.19, which were significantly different from the control group. These experimental results show that compound 6o may induce the accumulation of ROS and MDA in A549 and A549 / CDDP cells, causing oxidative ferroptosis of cells (such as Figure 7 shown).

[0159] Example 25 Solubility Test Experiment

[0160] Using HPLC detection conditions, 1 mg of the test compound was placed in a stoppered test tube and 2 mL of PBS solution (WISENT, China) was added. The test tube was sealed for use. After the test, the solubility was calculated by comparing with the prepared standard curve. The results showed that compared with the compound CY-16S-4A93, the solubility of most target compounds was improved to a certain extent (1.13-10.26 times). Among them, the target compounds (6p and 13a-d) with amino and cyano substitutions on the 3-position benzene ring of the coumarin parent nucleus had better water solubility, which was 8-10 times higher than the water solubility of the lead compound CY-16S-4A93.

[0161] Table 4

[0162]

[0163] Example 26 Experiment on the apoptosis of A549 and A549 / CDDP cells promoted by target compound 6o

[0164] First, culture the required A549 and A549 / CDDP cells, digest them with 0.25% trypsin (Beyotime) for 1-2 minutes, centrifuge (1000r, 10min) and collect the cells. The collected A549 cells were inoculated in a new 6cm culture dish, with the number of cells inoculated per dish being about 1*10 6 , placed in an incubator for 24 hours; add 1 mL of the test compound 6o at different concentrations (20, 40 and 80 nM) to each dish, and continue to culture in an incubator for 12 hours. Aspirate the drug-containing culture medium, wash the cells in the culture dish with PBS, centrifuge (1000r, 5min) and collect the cells; aspirate the supernatant in the centrifuge tube and add 100μL Annexin V-FITC binding solution, mix well; add 10μL PI staining solution and mix well; detect with a flow cytometer at room temperature with 10μLPI staining solution.

[0165] The experimental results show that ( Figure 8 As shown in the figure, compound 6o can induce apoptosis of A549 and A549 / CDDP cells in a concentration-dependent manner. With the increase of 6o administration concentration, the total apoptotic cells (Q2+Q3) in A549 cells increased from 8.80% to 86.72%, and the late apoptotic cells (Q2) and early apoptotic cells (Q3) were 1.81-0.92% and 6.99-85.80%, respectively; the total apoptotic cells (Q2+Q3) in A549 / CDDP cells increased from 16.24% to 59.30%, and the late apoptotic cells (Q2) and early apoptotic cells (Q3) were 10.60-29.20% and 5.60-30.10%, respectively. This experiment shows that 6o may inhibit the proliferation of A549 and A549 / CDDP cells through multiple pathways such as ferroptosis, promoting apoptosis, and interfering with the MER / ERK pathway, thereby achieving the ultimate purpose of killing tumor cells.

Claims

1. 3,4,8-Substituted coumarin-furoxan derivatives, It is characterized in that The derivative is a coumarin mother nucleus with benzyl and substituted phenethyl groups containing different substituents such as ortho, meta and para connected at the 3-position; alkyl, unsubstituted aryl and substituted aryl connected at the 4-position; substituted aryl alkanoate methyl connected at the 8-position; and a coupling product with furazan nitrogen oxide at the 7-position through two carbon side chains. The compound has a structure of structural formula I as shown in FIG1 , Where: R 1 is methyl, ethyl, propyl, phenyl, trifluoromethylphenyl, R 2 is o-, m-, p-methoxybenzyl; o-, m-, p-aminobenzyl; o-, m-, p-chlorobenzyl; o-, m-trifluoromethylbenzyl; p-bromobenzyl; m-cyanobenzyl; 3,5-dimethoxybenzyl; 3,4,5-trimethoxybenzyl; 3,5-dimethyltrifluoromethylbenzyl; 3,4-dichlorobenzyl; 2,6-dichlorobenzyl; 3,5-dichlorobenzyl; 3-chloro-4-fluorobenzyl; 3-fluoro-4-chlorobenzyl; 3-fluoro-5-chlorobenzyl; 4-aminophenethyl, R 3 It is 3,4,5-trimethoxyphenylacetyloxymethylene.

2. Use of the compound of formula I according to claim 1 in the preparation of a pharmaceutical preparation for inhibiting sensitive and resistant human tumor cells.

3. The use according to claim 2, It is characterized in that The sensitive tumor cells are sensitive tumor cell lines human breast cancer cells (MCF-7) and human non-small cell lung cancer cells (A549, H1299, H2030 and H1975).

4. The use according to claim 2, It is characterized in that The drug-resistant tumor cells are adriamycin-resistant breast cancer cells MCF-7 / ADR, paclitaxel-resistant A549 / T and cisplatin-resistant A549 / CDDP.

5. The use according to claim 2, It is characterized in that The compound of formula I inhibits the proliferation of tumor cells by releasing high concentrations of nitric oxide.

6. The use according to claim 2, It is characterized in that The compound of formula I has the effect of selectively inhibiting the proliferation of MDR tumor cells overexpressing P-gp by releasing high concentration of nitric oxide.

7. The use according to claim 2, It is characterized in that The compound of formula I can cause an increase in the level of intracellular reactive oxygen species (ROS) and accumulation of lipid peroxides (MDA), and can inhibit the proliferation of non-small cell lung cancer cells through multiple pathways such as ferroptosis and induction of apoptosis.

Citation Information

Patent Citations

  • 3-substituted coumarin furazan derivatives and application of derivatives in preparation of anti-multidrug resistance tumor drugs

    CN108658962A

  • Coumarin derivative containing 7-substituent and 8-substituent, preparation method and uses thereof

    CN109111419A

  • NO donor coumarin furazan conjugate and pharmaceutical application thereof

    CN113493449A

Cited By

  • Substituted benzenesulfonamide compound and application thereof

    CN120504619A